Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06375187
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-04-16
Brief Title:
Engineering Tumor Infiltrating Lymphocytes Injection GC203 TIL for the Treatment of Advanced Malignant Solid Tumors
Sponsor:
Shanghai Juncell Therapeutics
Organization:
Shanghai Juncell Therapeutics
Study Overview
Official Title:
A Phase I Study on Engineering Tumor Infiltrating Lymphocytes Injection GC203 TIL for the Treatment of Advanced Malignant Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
KUNLUN-001
Brief Summary:
A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes TIL for the treatment of Advanced Malignant Solid Tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None